4/A: Amylyx Pharmaceuticals CFO Corrects Beneficial Ownership in Amended SEC Filing

James M. Frates, CFO of Amylyx Pharmaceuticals, files an amended Form 4 to correct an overstatement of beneficially owned securities.

Summary

• James M. Frates, the Chief Financial Officer of Amylyx Pharmaceuticals, filed an amended Form 4 with the SEC on September 5, 2024.
• This amendment corrects an error in the original Form 4 filed on August 24, 2023, which overstated the number of securities beneficially owned by Frates by 32,500 shares.
• The correction pertains to an administrative error in reporting the aggregate number of shares beneficially owned as of the original transaction date of August 23, 2023.
• On August 23, 2023, Frates exercised a stock option to acquire 18,165 shares of common stock at a price of $6.88 per share.
• Following the reported transaction, Frates directly owns 73,841 shares and indirectly owns 19,482 shares through a trust.
• Frates also holds options to purchase 363,835 shares of Amylyx common stock.

Sentiment

Score: 6

Explanation: The document is a routine correction of a previous error in an SEC filing. While the error itself is slightly negative, the correction is a positive step towards transparency.

Positives

• The amended filing ensures accurate reporting of beneficial ownership, promoting transparency.

Negatives

• The original overstatement of shares indicates a potential lapse in internal controls or administrative oversight.

Risks

• Inaccurate reporting, even if corrected, can erode investor confidence.
• Continued errors in SEC filings could lead to regulatory scrutiny.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency and compliance with SEC regulations.

Comparison to Industry Standards

• Similar filings are common across publicly traded companies, such as Biogen (BIIB) and Vertex Pharmaceuticals (VRTX), where executives routinely report transactions in company stock.
• The correction of errors in SEC filings is also a standard practice, although it highlights the importance of robust internal controls to prevent such errors.

Key Dates